发明申请
US20050272738A1 Combined treatment with oxaliplatin and an epidermal growth factor receptor kinase inhibitor
审中-公开
联合奥沙利铂和表皮生长因子受体激酶抑制剂治疗
- 专利标题： Combined treatment with oxaliplatin and an epidermal growth factor receptor kinase inhibitor
- 专利标题（中）： 联合奥沙利铂和表皮生长因子受体激酶抑制剂治疗
-
申请号： US11145091申请日： 2005-06-03
-
公开(公告)号： US20050272738A1公开(公告)日： 2005-12-08
- 发明人: Jianping Chen , Brian Higgins , Kenneth Kolinsky
- 申请人： Jianping Chen , Brian Higgins , Kenneth Kolinsky
- 主分类号： A61K31/28
- IPC分类号： A61K31/28 ; A61K31/4706 ; A61K31/498 ; A61K31/517 ; A61K31/519 ; A61K31/5377 ; A61K33/24 ; A61K38/50
摘要：
The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and oxaliplatin combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and oxaliplatin combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva™).
信息查询
